News & Views
Investment to Support Technology Roll-Out
Jan 31 2018
Biomanufacturing company Univercells SA, (Gosselies, Belgium) has announced the successful closing of a €3 million ($3.56M) increase in a Series-A equity financing round, led by private investors from Europe and the US.
The capital injection will help enable the commercial introduction of the company’s viral micro-facility, with a first technology transfer anticipated for Q4 2018 within the framework of the Bill & Melinda Gates Foundation-supported program; it will also benefit the company’s recombinant platform development, both of which are aimed at providing a sufficient supply of high-quality biologics at an affordable price.
“We are very proud of this funding round and thankful for this wealth of support,” commented Hugues Bultot, co-founder and CEO of Univercells. “This successful capital increase is a real recognition of the work achieved so far, the innovative technology being developed and the clear expectations and roadmap set. It is highly encouraging to have seasoned industry experts demonstrate such tremendous confidence in Univercells, its ability to transform the industry with their willingness to contribute to our mission.”
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE